gMendel and genXone join forces in a trial project for the diagnosis of genetic disorders- #BHHMembersInitiatives
Home News gMendel and genXone join forces in a trial project for the diagnosis of genetic disorders- #BHHMembersInitiatives

gMendel and genXone join forces in a trial project for the diagnosis of genetic disorders- #BHHMembersInitiatives

OCTOBER 18, 2022 BHH News
BHH member gMendel® has signed a letter of intent to significantly expand its cooperation with Polish biotech company genXone. The two companies joined efforts earlier this year with a trial project for the diagnosis of genetic disorders. The current phase begins with negotiations on an investment agreement and the expected result is the innovative tool for diagnosing rare disease carriers that has global application potential. The particular investment marks the need of large medical biotech key players for immediate market adoption of the gMendel® Test. gMendel® and genXone have decided to expand the scope of their research and continue their cooperation in the development and launch of a novel tool based on the Phivea® platform and nanopore technology for the screening of carriers of rare genetic diseases, such as Spinal Muscular Atrophy, Fragile X and Cystic Fibrosis, among others. The project will commence after the conclusion of an investment agreement, the details of which will be negotiated in the coming weeks. The agreement is expected to regulate the terms and conditions of financing project efforts. Recognizing the global and long-term dimension of the cooperation, the companies are discussing new share issuance and a possible loan from genXone to gMendel®. Such an arrangement will guarantee adequate resources for the project and strengthen R&D cooperation between the companies. “This investment demonstrates genXone’s strong confidence in gMendel®’s proprietary technology and our shared vision to revolutionize the diagnosis of genetic disorders through the gMendel® Test as an accurate, affordable and rapid screening technology”, says Chris Kyriakidis, CEO and co-Founder of gMendel®. “Over the past months, our partnership has matured, and the current investment is an attractive opportunity to expand the delivery capability of the gMendel® Test in a wider range of genetic disorders and growing its availability in first instance to the people of Poland through genXone’s access to a vast network of diagnostic laboratories. This is a winning innovation on all levels: for patients, for diagnostic laboratories, for medical professionals and for national healthcare systems.” “This agreement means concrete benefits for both partners. Through synergy and joint efforts, we will develop an innovation on a global scale – a test for diagnosing rare disease carriers, based on Phivea® platform and nanopore sequencing technology. Having the operational potential, advanced bioinformatics competence and experience in implementing such solutions outside the laboratory will allow us to develop a universal and accessible screening tool ready for deployment anywhere in the world. The cooperation with foreign partners, which we are developing systematically, is the realization of one of the key goals of our strategy for the global dissemination of advanced genetic testing methods and tangible business proof that it is possible – and profitable – to make money and create new quality on biotechnology and molecular genetics,” emphasizes Michal Kaszuba, CEO of genXone. The planned cooperation includes at least three stages. The negotiation phase, which is currently starting, is expected to create a financial framework for the joint venture. Successful conclusion of the talks will open the first research and development stage. Its aim is to develop a basic diagnostic test for carrying rare diseases (so-called BCT – basic carrier test, which includes Fragile X, Cystic Fibrosis and Spinal Muscular Atrophy). Satisfactory results of the developed test should lead to the development of a test for the broad diagnosis of rare diseases during pregnancy (NIPT – Non Invasive Prenatal Test) or in newborns in the future. Know more about the gMendel® Test here.
June 12, 2024 BHH News
Siemens Healthineers and Barcelona Health Hub sign partnership to drive breakthrough innovations for equitable, quality healthcare
This partnership opens a collaboration line between both entities to advance towards a future where medical care and technological advancements help healthcare professionals deliver high-quality care, thus achieving the best possible outcomes for patients.
Read more
June 10, 2024 BHH News
Menarini and Barcelona Health Hub join forces to promote the incorporation of digital health innovation into the healthcare field
Open collaboration and co-creation are the pillars for generating innovation in healthcare. Technological and scientific advances can be significantly accelerated when collaborative environments are fostered.
Read more
June 06, 2024 BHH News
BHH Podcast - Mediktor
BHH member Mediktor joins in this episode with CEO Cristian Pascual.  Listen to Cristian share his journey in revolutionizing healthcare through AI-driven medical triage. 
Read more
June 05, 2024 BHH News
CHV-FHSC signs a strategic alliance with Barcelona Health Hub
This alliance is to carry out joint activities to share concerns and knowledge that lead to the development of new technology projects.
Read more
June 05, 2024 BHH News
BHH ON AIR with Vodafone Business at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 29, 2024 BHH News
Teladoc Health joins Barcelona Health Hub to support its mission to advance innovation in digital health
Teladoc Health, the world's leading virtual care company, with revenues of 2.6 billion USD in 2023, joins Barcelona Health Hub. 
Read more
May 22, 2024 BHH News
Check out the state of Digital Health in Catalonia
This is your chance to dive deep into the state of digital health in Catalonia with this elaborated by ACCIÓ, in collaboration with Barcelona Health Hub.
Read more
May 09, 2024 BHH News
Explore the 'Sandbox of the System' at the Stage Hospital de la Santa Creu i Sant Pau
Explore the Hospital de la Santa Creu i Sant Pau Stage as the latest track of the Health Revolution Congress on May 16th!
Read more
May 09, 2024 BHH News
BHH ON AIR with Fundació Sant Pau at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 03, 2024 BHH News
Stage Biocat: New Pathways for the Adoption of Healthcare Innovation in Catalonia
Discover the Biocat morning session as part of the Health Revolution Congress on May 16th.
Read more